logo-loader
RNS
Abcam PLC

ABCAM PLC - Transaction complete between Abcam and Expedeon

RNS Number : 3972Y
ABCAM PLC
02 January 2020
 

2 January 2020

ABCAM PLC

("Abcam" or "the Group")

 

Completion of transaction between Abcam and Expedeon

Abcam plc (AIM LSE: ABC), a global leader in the supply of life science research tools, today announces that the transaction to acquire Expedeon Ltd, Innova Biosciences Ltd. and TGR BioSciences (the "Proteomics and Immunology business") from Expedeon AG ("Expedeon") (the "Acquisition") has now completed. 

As announced in November 2019, the Acquisition secures a complementary portfolio of leading protein conjugation technologies and products for Abcam, including well-known industry brands Lightning-Link® and CaptSureTM.

Commenting on the completion of the Acquisition, Alan Hirzel, CEO of Abcam, said:

"We are delighted to have completed this transaction and welcome our new colleagues to Abcam. Expedeon's portfolio of products and technology, combined with Abcam's antibody and protein strengths, place us well to address the growing need for antibody conjugation and multiplexing solutions."

 

Ondra LLP provided advice to the Board of Directors of Abcam in relation to this transaction.

 

For further information, please contact:

Abcam

+ 44 (0) 1223 696 000

Alan Hirzel, Chief Executive Officer

Gavin Wood, Chief Financial Officer

James Staveley, VP Investor Relations

 

J.P. Morgan Cazenove - Nominated Advisor and Joint Corporate Broker

+44 (0) 20 7742 4000

James Mitford / Hemant Kapoor

 

Numis - Joint Corporate Broker

+44 (0) 20 7260 1000

Garry Levin / Duncan Monteith

 

FTI Consulting (Media enquiries)

+44 (0) 20 3727 1000

Ben Atwell / Natalie Garland-Collins

 

Ondra LLP, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting solely for the Board of Directors of Abcam and no one else in connection with the matters described in this announcement and will not be responsible to anyone other than the Board of Directors of Abcam for providing the protections afforded to clients of Ondra LLP, nor for providing advice in relation to this announcement.  Neither Ondra LLP nor any of its respective subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Ondra LLP in connection with this announcement or any matter referred to herein.

 

Forward looking statements

This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam Group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam Group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements. The Abcam Group does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law.

 

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.

With eleven sites globally, many of Abcam's 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRBGBDDSBXBGCB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read